Sana Biotechnology, Inc. (SANA)
Automate Your Wheel Strategy on SANA
With Tiblio's Option Bot, you can configure your own wheel strategy including SANA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SANA
- Rev/Share 0.0
- Book/Share 0.88
- PB 2.4999
- Debt/Equity 0.4367
- CurrentRatio 3.4
- ROIC -0.5079
- MktCap 496221000.0
- FreeCF/Share -0.9424
- PFCF -2.2163
- PE -2.5047
- Debt/Assets 0.205
- DivYield 0
- ROE -0.7646
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | SANA | Citizens JMP | Market Perform | Mkt Outperform | -- | $5 | March 18, 2025 |
| Initiation | SANA | Jefferies | -- | Buy | -- | $7 | March 14, 2025 |
| Upgrade | SANA | TD Cowen | Hold | Buy | -- | -- | Jan. 8, 2025 |
News
Rosen Law Firm Urges Sana Biotechnology, Inc. (NASDAQ: SANA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Published: March 24, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of Sana Biotechnology, Inc. (NASDAQ: SANA) securities between March 17, 2023 and November 17, 2024, inclusive (the “Class Period”). Sana is a biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations tha.
Read More
SANA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Published: March 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or "the Company") (NASDAQ:SANA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period").
Read More
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers - SANA
Published: March 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA) and certain officers. The class action, filed in the United States District Court for the Western District of Washington, and docketed under 25-cv-00512, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Sana securities between March 17, 2023 and November 4, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the …
Read More
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Sana Biotechnology, Inc. (SANA) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
ATLANTA, March 24, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Sana Biotechnology, Inc. (“Sana” or the “Company”) (NASDAQ: SANA). The lawsuit alleges that Defendants made false and/or misleading statements and/or failed to disclose material facts regarding Sana's business, operations, and prospects, including allegations that: (i) Sana was at significant risk of having insufficient funds to maintain its current operations and advance one or more of its product candidates; (ii) SC291 in oncology, SC379, and SG299 were less promising than Defendants had led investors to believe; (iii) in order to preserve cash and advance its …
Read More
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Sana Biotechnology, Inc. (SANA)
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Western District of Washington on behalf of all persons or entities who purchased or otherwise acquired Sana Biotechnology, Inc. (“Sana” or the “Company”) (NASDAQ: SANA) securities between March 17, 2023 and November 4, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company's investors under the federal securities laws.
Read More
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: March 23, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Read More
About Sana Biotechnology, Inc. (SANA)
- IPO Date 2021-02-04
- Website https://www.sana.com
- Industry Biotechnology
- CEO Dr. Steven D. Harr M.D.
- Employees 194